Document Detail


HTLV infection and the eye.
MedLine Citation:
PMID:  23047174     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Human T-cell lymphotropic virus (HTLV) is the first discovered retrovirus causing malignancy in human. HTLV infection affects host's ocular tolerance and causes various diseases in the eye. Here we discuss the manifestations, mechanisms, treatments, and future directions of HTLV-related ocular diseases. RECENT FININGS: Recent serological researches showed that the number of HTLV-1 carriers in metropolitan area was increasing, although seroprevalence of HTLV-1 in general population was decreased after screening serological tests in blood donors started. The most common clinical entity of uveitis was still HTLV-1 uveitis in HTLV-1 highly endemic area, but prevalence of HTLV-1 uveitis varies in different parts of the world. As for treatment of inflammation, tacrolimus and 5-azacytidine were reported to be effective for autoimmune manifestations in HTLV-1-related overlap syndrome (deratomyositis/Sjogren's syndrome) and HTLV-1-related myelodysplastic syndrome. Interleukin-2 receptor targeted therapies improved scleritis in patients with adult T-cell leukemia/lymphoma caused by HTLV-1. Basic researches identified that HTLV-1 tax and HTLV-1 basic leucine zipper factor play critical roles in the HTLV-1-related disease and are now being investigated as targeted therapies.
SUMMARY: Development of modern molecular biology makes it possible to reveal deep insights of HTLV-1-related ocular diseases. Although effective therapies based on basic researches have been reported, further endeavor is necessary to establish much more specific treatments of the ocular diseases.
Authors:
Koju Kamoi; Manabu Mochizuki
Related Documents :
23023494 - Outbreaks of blackleg in scottish cattle.
22847214 - Parkinson's disease, l-dopa, and endogenous morphine: a revisit.
24642034 - Inequalities in the incidence of infectious disease in the north east of england: a pop...
23532794 - Short, fine and who asbestos fibers in the lungs of quebec workers with an asbestos-rel...
2330524 - Features of systemic sclerosis (scleroderma) in south african goldminers.
1851694 - Deglycosylation of alpha 1-proteinase inhibitor is impaired in the faeces of patients w...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in ophthalmology     Volume:  23     ISSN:  1531-7021     ISO Abbreviation:  Curr Opin Ophthalmol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-10     Completed Date:  2013-04-04     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  9011108     Medline TA:  Curr Opin Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  557-61     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Azacitidine / therapeutic use
Enzyme Inhibitors / therapeutic use
Human T-lymphotropic virus 1 / immunology,  isolation & purification
Humans
Immunosuppressive Agents / therapeutic use
Keratoconjunctivitis Sicca / diagnosis*,  drug therapy,  virology
Leukemia-Lymphoma, Adult T-Cell / diagnosis*,  drug therapy,  virology
Tacrolimus / therapeutic use
Uveitis / diagnosis*,  drug therapy,  virology
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 320-67-2/Azacitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Update on ocular tuberculosis.
Next Document:  Two-Photon-Activated Ligand Exchange in Platinum(II) Complexes.